Login / Signup

Meta-Analysis Comparing Potent Oral P2Y12 Inhibitors versus Clopidogrel in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.

Matteo CasulaFederico FortuniMarco FerliniFrancesca FabrisLuigi Oltrona ViscontiSergio Leonardi
Published in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2021)
In patients receiving OAC therapy for AF after a recent PCI, potent oral P2Y12 inhibitors increase the risk of clinically relevant bleeding compared with clopidogrel, with no evident benefit in terms of MACE reduction.
Keyphrases